![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H24FN3O3 |
Molar mass | 397.450 g·mol−1 |
3D model (JSmol) | |
| |
|
MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is a potent agonist for cannabinoid receptors and that has been sold online as a designer drug. [1] [2] The structure of MDMB-FUBINACA contains the amino acid, 3-methylvaline[ citation needed ], also known as l-tert-leucine. [3] MDMB-FUBINACA has Ki values of 1.14nM at CB1 and 0.1228nM at CB2 and EC50 values of 0.2668nM at CB1 and 0.1411nM at CB2. [4]
There have been a large number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid, mainly in Russia and Belarus. MDMB-FUBINACA was first reported in 2014 and quickly gained a reputation as the most deadly synthetic cannabinoid drug sold by 2015. [5] Up to 700 hospitalisations and 25 deaths were initially linked to MDMB-FUBINACA in media and government reports, and subsequent testing confirmed that at least 1000 hospitalisations and 40 deaths had occurred as a consequence of intoxication by MDMB-FUBINACA as of March 2015. [6] [7]
In the United States, MDMB-FUBINACA is a Schedule I controlled substance. [8]
As of October 2015, MDMB-FUBINACA is a controlled substance in Belarus, Russia, [9] and China. [10]
In July 2021, it was included in Table II-A in the list of prohibited drugs of Portugal.[ citation needed ]